PROCESS FOR PREPARING BONE MARROW STEM CELLS, AND COMPOSITION RELATED THERETO

• US 20070098699A1
• Filed: 11/30/2006
• Published: 05/03/2007
• Est. Priority Date: 02/28/2005
• Status: Abandoned Application

• Current Assignee: Donnie Rudd
• Original Assignee: Donnie Rudd
• Inventors: RUDD, Donnie
• Application Number:
  US11/565,076
• Publication Number:
  US 20070098699A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A01N 1/02 Preservation of living parts
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61K 33/34 Copper; Compounds thereof
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 38/193 Colony stimulating factors [CSF]
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 33/02 Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• CPC Class Codes: A61P 33/06 Antimalarials
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 : specific for leukemia
• CPC Class Codes: A61P 37/02 : Immunomodulators
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 7/00 : Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/04 : Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 7/06 : Antianaemics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 2501/125 : Stem cell factor [SCF], c-kit ligand [KL]
• CPC Class Codes: C12N 2501/22 : Colony stimulating factors (G-CSF, GM-CSF)
• CPC Class Codes: C12N 5/0647 : Haematopoietic stem cells; Uncommitted or multipotent progenitors
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Process for preparing a composition comprising TVEMF-expanded bone marrow stem cells, anti the composition resulting therefrom.

Claims

1. Bone marrow stem cells from a mammal, wherein said bone marrow stem cells are TVEMF-expanded.

2. A bone marrow stem cell composition comprising:

the bone marrow stem cells of claim 1;

and

an acceptable carrier.

3. The composition of claim 2, wherein said acceptable carrier is at least one of the group consisting of plasma, blood, albumin, cell culture medium, buffer and cryopreservative;

and wherein said composition optionally further comprises at least one of a growth factor, a copper chelating agent, and a hormone.

4. The composition of claim 3, wherein said growth factor if present is G-CSF and wherein said copper chelating agent if present is D-penicillamine.

5. The composition of claim 2, wherein said composition is at a temperature sufficient to cryogenically preserve the peripheral blood stem cells.

6. The composition according to claim 2, wherein a cryopreservative is present in an amount sufficient for cryopreservation of said cells and wherein said composition is at a temperature of for about −

120°

C. to about −

196°

C.

7. The composition according to claim 6, wherein said temperature is from about −

130°

C. to about −

150°

C.

8. The composition according to claim 6, wherein said composition is free of toxic material.

9. The composition according to claim 3, wherein said composition comprises a total amount of a cryopreservative selected from the group consisting of 20 to 400% dimothyl sulfoxide solution in 60 to 80% amino acid-glucose solution;

15 to 25% hydroxyethyl starch solution;

4 to 6% glycerol, 3 to 5% glucose and 6 to 10% dextran T10;

15 to 25% polyethylene glycol; and

75 to 85% amino acid-glucose solution.

10. The composition of claim 2, wherein said composition is free of toxic material.

11. A process for preparing a bone marrow stem cell composition comprising the steps of:

placing a bone marrow mixture in a culture chamber of a TVEMF-bioreactor; and

subjecting the bone marrow mixture to a TVEMF; and

TVEMF-expanding the bone marrow stem cells in the TVEMF-bioreactor prepare the bone marrow stem cell composition.

12. The process of claim 11, further comprising the steps of transferring the TVEMF-expanded cells of the bone marrow stem cell composition into a cryogenic container having a temperature, and lowering the temperature of the cryogenic container to a temperature of from −

120°

C. to −

196°

C. at a controlled rate.

13. The process of claim 12, further comprising a step of removing toxic material from the bone marrow stem cell composition prior to lowering the temperature to a temperature of from −

120°

C. to −

196°

C. at a controlled rate.

14. The process of claim 12, further comprising, after the step of lowering the temperature, a step of maintaining the temperature of the cryogenic container to a temperature of from −

120°

C. to −

196°

C., for a period of time.

15. The process of claim 14, wherein said period of time is at least 1 year.

16. The process of claim 14, further comprising, after said lowering and maintaining of temperature, a step of increasing the temperature of the cryogenic container at a controlled rate to a temperature suitable for introducing the bone marrow stem cell composition to a mammal.

17. The process of claim 16, wherein toxic material has been removed from said increased temperature bone marrow stem cell composition.

18. The process of claim 12, further comprising the step of adding a cryopreservative to the TVEMF-expanded cells of the bone marrow stem cell composition before the step of lowering the temperature.